Citius Pharmaceuticals to Present at the ThinkEquity Conference

CRANFORD, N.J., May 1, 2019 /PRNewswire/ --Citius Pharmaceuticals, Inc. (“Citius”) (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the Company will present at the ThinkEquity Conference on Thursday, May 2, 2019 at 8:30AM ET. The conference is being held at The Mandarin Oriental Hotel in New York City.

During the conference, Executive Chairman, Mr. Leonard Mazur will be giving the presentation as well as answering questions from investors. Citius Pharmaceuticals recently raised $5.3 million with 37% from coming from Mr. Leonard Mazur, Executive Chairman of Citius Pharmaceuticals and Mr. Myron Holubiak, President and CEO of Citius Pharmaceuticals.

Citius Pharmaceuticals, Inc. will also be available for one-on-one meetings. To arrange a meeting with the Company, please contact Mr. Andrew Scott: ascott@citiuspharma.com.

About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs; by using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit www.citiuspharma.com.

Contact:
Andrew Scott
Vice President, Corporate Development
(o) 908-967-6677
ascott@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-thinkequity-conference-300841248.html

SOURCE Citius Pharmaceuticals, Inc.